Oscillating amplification reaction for nucleic acids
11293058 · 2022-04-05
Assignee
Inventors
Cpc classification
C12Q2522/101
CHEMISTRY; METALLURGY
C12Q2527/125
CHEMISTRY; METALLURGY
C12P19/34
CHEMISTRY; METALLURGY
B01L3/502723
PERFORMING OPERATIONS; TRANSPORTING
C12Q2527/125
CHEMISTRY; METALLURGY
C12Q2522/101
CHEMISTRY; METALLURGY
International classification
B01L3/00
PERFORMING OPERATIONS; TRANSPORTING
Abstract
One embodiment of the present invention provides for a method for amplifying a template of nucleic acid target sequence contained in a sample. The method includes contacting the sample with an amplification reaction mixture containing a primer complementary to the template of nucleic acid target sequence. A temperature of the reaction is oscillated between an upper temperature and a lower temperature wherein the change in temperature is no greater than about 20° C. during a plurality of temperature cycles. The template of nucleic acid target sequence is amplified.
Claims
1. A method for amplifying a template of nucleic acid target sequence contained in a sample, comprising: contacting the sample with an amplification reaction mixture comprising a primer complementary to the template of nucleic acid target sequence, the primer having a melting temperature ≥65° C.; oscillating a temperature of the reaction between an upper denaturation temperature and a lower annealing temperature, wherein a change between the upper denaturation temperature and the lower annealing temperature is no greater than about 20° C. during a plurality of temperature cycles, and the upper denaturation temperature is no greater than 85° C.; and amplifying the template of nucleic acid target sequence.
2. The method of claim 1, wherein the change in temperature is no greater than 15° C.
3. The method of claim 1, wherein upon reaching the upper denaturation temperature or the lower annealing temperature, the temperature is maintained for a set period of time within a temperature fluctuation.
4. The method of claim 1, wherein upon reaching an upper denaturation or lower annealing temperature within the temperature range, the temperature is varied to the other temperature.
5. The method of claim 1, wherein the lower annealing temperature is no less than 50° C.
6. The method of claim 1, wherein the template of nucleic acid target sequence is single stranded or double stranded DNA or RNA.
7. The method of claim 1, wherein the length of the target nucleic acid may be less than 1000 bp.
8. The method of claim 1, wherein the amplification reaction mixture comprises a pair of primers which bind to opposite strands of the template of nucleic acid.
9. The method of claim 8, wherein the pair of primers have a length and a GC content so that the melting temperature is ≥65° C.
10. The method of claim 8, wherein the pair of primers have a length of between 35-70 base pairs.
11. The method of claim 8, wherein the pair of primers have a length of between 40-47 base pairs.
12. The method of claim 1, wherein the amplification reaction mixture comprises: monovalent cation, divalent cation, dNTPs; DNA Polymerase, and a nucleic acid destabilizing agent comprising at least one of DMSO and formamide.
13. The method of claim 12, wherein the divalent cation is a salt selected from the group consisting of magnesium, manganese, copper, zinc, and any combination thereof.
14. The method of claim 12, wherein the monovalent cation is a salt selected from the group consisting of sodium, potassium, lithium, rubidium, cesium, ammonium, and any combination thereof.
15. The method of claim 12, wherein the DNA polymerase is a thermostable DNA polymerase.
16. The method of claim 12, wherein the nucleic acid destabilizing agent is at a concentration between 8 and 15 volume percent.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1) The accompanying drawings, which are incorporated into and form a part of the specification, illustrate an embodiment of the present invention and, together with the description, serve to explain the principles of the invention. The drawings are only for the purpose of illustrating a preferred embodiment of the invention and are not to be construed as limiting the invention. In the drawings:
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
DETAILED DESCRIPTION OF THE INVENTION
(21) As used throughout the specification and claims, the term ‘nucleic acid’ means single stranded or double stranded DNA, RNA, or DNA/RNA hybrid molecules. Single stranded nucleic acids may have secondary structure such as hairpin, loop, and stem elements. Double stranded or single stranded nucleic acids may be linear or circular. Double stranded nucleic acids may be intact or nicked. Double stranded molecules may be blunt-ended or have single strand overhanging ends. Nucleic acid samples may be isolated from cells or viruses and may include chromosomal DNA, extra-chromosomal DNA including plasmid DNA, recombinant DNA, DNA fragments, messenger RNA, ribosomal RNA, transfer RNA, double stranded RNA or other RNAs that occur in cells or viruses. Nucleic acid may be isolated from any number of sources such as agriculture, food, environmental, fermentations, or biological fluids such as saliva, blood, nasal or lung aspirates, cerebrospinal fluid, sputum, stool, milk, swabs of mucosal tissues, tissue samples, or cells. Nucleic acid may be isolated, cloned or synthesized in vitro. Within the described nucleic acids above, individual nucleotides may be subject to modification or chemical alterations such as methylation. These modifications or alterations may arise naturally or by in vitro synthesis.
(22) As used throughout the specification and claims, the terms ‘target nucleic acid’ or ‘template nucleic acid’ mean a single stranded or double stranded DNA or RNA fragment or sequence that is intended to be selectively amplified. The size of the nucleic acid to be amplified is defined by upstream (5′) and downstream (3′) boundaries and may be less than 500 bp, preferably less than 250 bp, and more preferably less than 150 bp and more preferably less than 100 bp. The target nucleic acid may be a fragment contained within a longer double stranded or single stranded nucleic acid or may be an entire double stranded or single stranded nucleic acid.
(23) As used throughout the specification and claims, the term ‘duplex’ means a DNA or RNA nucleic acid molecule that is double stranded in whole or in part.
(24) As used throughout the specification and claims, the term ‘thermal cycle’ means the repeated temperature fluctuation necessary for nucleic acid amplification to occur. The thermal cycle may include, but is not limited to, a high temperature melting or denaturation step, and a low temperature annealing or hybridization step.
(25) As used throughout the specification and claims, the terms ‘melting’ or ‘denaturation’ mean separating all or part of two complementary strands of a nucleic acid duplex with high temperature. The melting or denaturation temperature may be influenced by the length and sequence of the oligonucleotide primer, the concentration of duplex destabilizing reagents such as DMSO and formamide, and the ionic strength or pH of the solution.
(26) As used throughout the specification and claims, the terms ‘annealing’ or ‘hybridization’ mean the sequence-specific binding of an oligonucleotide primer to a single-stranded nucleic acid template. The primer may bind only to its complementary sequence on one of the template strands and no other region of the template. The specificity of annealing or hybridization may be influenced by the length and sequence of the oligonucleotide primer, the temperature at which binding is performed, the concentration of duplex destabilizing reagents such as DMSO and formamide, and the ionic strength or pH of the solution.
(27) As used throughout the specification and claims, the term ‘primer’ means a single stranded nucleic acid or oligonucleotide capable of binding to a single stranded region on a target nucleic acid in a sequence-specific manner that allows polymerase-dependent replication of the target nucleic acid.
(28) As used throughout the specification and claims, the term ‘OPCRar’ means Oscillating PCR Amplification Reaction which is an in vitro technique for amplifying nucleic acids using variations in temperature less than the typical amplification techniques, for example less than 20° C., preferably less than 15° C. and more preferably less than 10° C. between the denaturation temperature and the annealing temperature.
(29) As used throughout the specification and claims, the term ‘accessory protein’ refers to any protein capable of stimulating activity, for example, a thermostable single stranded binding protein (SSB), for example rec A or RPA (Replication Protein A but not limited thereto.
(30) In an embodiment of the invention, a method is provided for exponentially amplifying a specific nucleic acid target by thermal cycling where temperature variation is preferably less than 20° C., more preferably less than 15° C., and even more preferably less than 10° C. This includes the steps of providing a single-stranded template of the nucleic acid to be amplified, oligonucleotide primers for hybridization to the nucleic acid template, using the hybridized oligonucleotide primers to synthesize a double-stranded extension product which is complementary to the template strand by means of a DNA polymerase, and repeating of the above steps to exponentially amplify a select nucleic acid target.
(31) Referring now to
(32) In additional embodiments of the invention, thermal cycling involves temperature oscillation or cycling between two temperatures with a ΔT of preferably no more than 20° C., more preferably no more than 15° C., and even more preferably less than 10° C. The higher of the two temperatures may be sufficient to denature the double stranded target DNA, or preferably result in only partial denaturation of the double stranded DNA target. Upon reaching either the high or low temperature, said temperature is maintained for a set period of time or, preferably, immediately varied to the other temperature.
(33) In additional embodiments of the Invention, the nucleic acid target may be a double stranded nucleic acid such as double stranded DNA, or a single stranded nucleic acid such as single stranded RNA or DNA. If the target nucleic acid is double stranded, it must be denatured either entirely or partially by heat, or enzymatically, to form a single stranded template or template region necessary for DNA polymerase activity and amplification. The length of the target nucleic acid may be less than 1000 bp, preferably less than 250 bp, and more preferably less than 150 bp.
(34) In additional embodiments of the invention, the oligonucleotide primers used for target nucleic acid amplification are a pair of primers which bind to opposite strands of a specific double stranded target nucleic acid, where one primer binds upstream at the 5′ end, and one primer binds downstream at the 3′ end of the target. Under multiplexing conditions, more than one oligonucleotide primer pair may be used to simultaneously amplify multiple nucleic acid targets in the same reaction mixture. The oligonucleotide primers may have a length and GC content so that the melting temperature is greater than 65° C. under universally accepted PCR buffer conditions, preferably greater than 70° C.
(35) In additional embodiments of the invention, the DNA polymerase used is preferably selected from Taq DNA polymerase, VentR DNA polymerase, DeepVentR DNA polymerase, and similar thermostable DNA polymerases. Preferably, the DNA polymerase possesses a strand-displacing activity and does not contain a 3′.fwdarw.5′ exonuclease activity (see
Other—Thermalphilic Polymerase Possibilities
(36) Thermophilic DNA Polymerase
(37) Polymerase and (Vender)
(38) VentR® (NEB)
(39) VentR (exo-)® (NEB)
(40) Deep Vent (NEB)
(41) Deep VentR (exo-) (NEB)
(42) Tag (NEB)
(43) PyroScript (Lucigen)
(44) PyroPhage® 3173, Wildtype (Lucigen)
(45) LongAmp Tag (NEB)
(46) Bst Polymerase
(47) Phire Hot Start II (NEB)
(48) Phusion High Fidelty DNA Polymerase (NEB)
(49) Phusion (NEB)
(50) Phusion® Flash (NEB)
(51) 9 Nm (NEB)
(52) DyNAzyme II Hot Start (NEB)
(53) DyNAzyme EXT (NEB)
(54) DreamTag (Fermentas)
(55) Tag (native) (Ferrnentas)
(56) Maxima® Hot Start Tag (Fementas)
(57) Pfu (recombinant), (Fermentas)
(58) Bsm (large fragment), (Fermentas)
(59) TrueStart™ Hot Start Tag (Fermentas)
(60) Tfi (Invitrogen)
(61) AmpiTag® (Invitrogen)
(62) AmpliTag Gold® (Invitrogen)
(63) Platinum® Pfx
(64) In additional embodiments of the invention, the reaction mixture preferably comprises a single stranded binding protein (SSB) such as T4 gene 32 protein, or thermal stable SSB isolated and cloned from a themophilic organism.
(65) Additionally, the enzyme preparation includes a single or double stranded nucleic acid destabilizing agent such as dimethylsulfoxide (DMSO) or formamide, preferably at a concentration of 8-15% of the total reaction volume. Alternatively other reagents such as glycerol deaza-dGTP, 3 dazopurein, dITP may be utilitzed alone or in combination with each other or the prior list of agents.
(66) Embodiments of this invention are ideally suited for use in low cost, point-of-care nucleic acid diagnostics in which a microfluidic layer is positioned over a heating element. By reducing temperature range cycling requirements, relatively simple heating with passive cooling mechanisms can be used to rapidly cycle temperature of a reaction solution. Lower maximum temperatures during thermal cycling minimize fluid evaporation which may negatively impact the overall amplification reaction. More importantly, the robustness of the amplification is greatly improved comparing to the conventional PCR process giving the new method is able to accommodate temperature fluctuation (imprecise temperature control) during a amplification process. The specific reaction chemistry of the invention was shown to work over a wide range of melting (e.g. 70-105° C., essentially insensitive to bubbling) and hybridization temperatures eliminating the need for uniform temperature throughout the entire reaction volume. Finally, embodiments of the invention perform well in the presence of alcohol, and salt (e.g. ˜10% ethanol), greatly reducing the stringency of up-front nucleic acid isolation methodologies through the elimination of a centrifugation, heat-dry or vacuum step between alcohol-based washing (e.g. ethanol or isopropanol) and nucleic acid elution step involved conventional nucleic acid extraction chemistry.
(67) Embodiments of this invention include the detection of pathogens in a biological sample where a nucleic acid of the pathogen is the target nucleic acid. Alternatively, the invention may be used to detect differences in chromosomal DNA, where a fragment of chromosomal DNA is the target nucleic acid. In this way, single nucleotide polymorphisms may be detected in the target nucleic acid from the same or different sources.
(68) Embodiments of the amplification technology of the present invention are referred to as an ‘Oscillating PCR Amplification Reaction’ (OPCRar). OPCRar is based upon, but not limited to, the combined use of double stranded destabilizing agents which lower the reaction melting temperature, and oligonucleotide primers of unusually high melting temperature (Tm) to raise the annealing temperature in a given thermal cycle. In this way, in vitro amplification of a target nucleic acid may be performed by rapid thermal cycling between temperatures preferably differing by 20° C., more preferably less than 15° C., and even more preferably less than 10° C. (
(69) The OPCRar method is based upon, but not limited to, the combined use of nucleic acid destabilizing agents which lower the reaction melting temperature, and two oligonucleotide primers of unusually high melting temperature (Tm) to raise the annealing temperature during thermal cycling. For a given target nucleic acid, one oligonucleotide primer preferably hybridizes to the 5′-end of the sense strand containing the target sequence, and one primer preferably hybridizes to the 5′-end of the anti-sense strand containing the reverse-complementary target sequence. OPCRar preferably utilizes, but is not limited to, the use of a strand displacing DNA polymerase without exonuclease activity to further lower the melting or denaturation temperature necessary for efficient target nucleic acid amplification. OPCRar may amplify a target nucleic acid in the presence or absence of an accessory protein. Any specific OPCRar system may be optimized by addition, subtraction, or substitution of components within the mixture.
(70) This amplification technology has improved characteristics over other amplification methodologies reported in prior art in the context of low-cost, rapid, point-of-care nucleic acid diagnostics. Unlike the above described nucleic acid amplification methodologies, the OPCRar system, enabled by its robust enzymatic process is robust, fast and tolerant to temperature fluctuations of a low cost heating device, thus ideally suited for low-cost, point-of-care applications. By minimizing the temperature differentials encountered during thermal cycling, OPCRar combines the speed and reliability of PCR with the lowered Instrumentation requirements of isothermal amplification methodologies.
(71) The OPCRar system's simplified thermal cycling requirement is ideally suited for passive-cooling instrumentation, where heat may be applied to one surface of a chamber and cooling occurs through heat dissipation to the atmosphere on the opposing surface. Such passive-cooling dramatically lowers the cost and complexity of any nucleic acids diagnostics device. Passive-cooling has been previously reported for use in diagnostics devices, however, these devices have employed conventional PCR cycling assay chemistry to amplify target nucleic acids limiting the rate of reaction (Luo et. al. Nuc Acids Res. 2005; Wilding et. al., Nuc. Acids. Res. 1996; Burke et. al., Science 1998). Another advantage of OPCRar is that efficient nucleic acid amplification may occur over a wide range of melting and annealing temperatures and consequently requires less stringent temperature control mechanism. In the construction of miniaturized nucleic acid diagnostics, maintenance of uniform temperature throughout the entire reaction volume can be challenging, with a particularly high temperature gradient occurring between the heated and unheated sides of the reaction chamber. Such temperature variation may result in inefficient amplification using conventional PCR or isothermal reaction chemistries. OPCRar, through the use of the combination of robust polymerase, destabilizing reagent and other polymerase accessory factors, is designed to minimize problems associated with precise temperature regulation and maintenance; so long as the coolest regions of the reaction chamber observe the minimal possible melt temperature and the maximal possible annealing temperature for a given nucleic acid target the reaction will progress efficiently, even if other regions of the reaction volume vary by >10° C. Moreover, the robust OPCRar nature of amplification chemistry along with the minimal power/energy consumption enables rapid and efficient amplification reaction at much large volume (e.g. 20 μl instead sub μl in a typical μPCR chips) greatly relaxed the stringency of the up-front sample-preparation/nucleic acid isolation process (in terms of obtain sub μl of input template that is both highly concentrated and ultra-pure nucleic acid free of any trace contaminant e.g. salt and ethanol carry over and inhibitory substance) and requirement of ultra-high concentration and ultra-pure of PCR enzymes and bioeagents.
Solvent Reagents
(72) Solvents such as DMSO and formamide are known to lower the melting temperature of duplex nucleic acids by ˜0.5-0.7° C. for every 1% volume added. These reagents are often used to improve amplification efficiency of target nucleic acids containing high GC content and, thus, high Tm to facilitate complete denaturation of difficult-to-melt double stranded templates. Commonly, PCR thermal cycling temperatures are kept constant upon incorporation of duplex destabilizing agents into PCR reactions. In contrast, OPCRar preferably utilizes the addition of uniquely high concentrations of DMSO to dramatically lower the melting temperature of the thermal cycle. In conventional PCR, DMSO is rarely used above 10% v/v due to the loss of polymerase activity associated with high concentrations of these reagents in conjunction with the high temperatures (generally greater than 90° C.) of the melting stage. The OPCRar system and method, on the other hand, preferably uses DMSO concentrations between 10 and 15%. Unexpectedly, this amount of DMSO does not produce significant loss of polymerase activity.
(73) Referring now to
(74) The conventional PCR enzyme, e.g. Taq DNA polymerase reaction mixture is extremely sensitive to any trace amount of alcohol, e.g. ethanol, whereas in one embodiment of the invention the novel reaction mixture is exceedingly resistant to inhibition by ethanol. Referring now to
(75) Use of VentR(exo-) DNA polymerase and Et SSB under typical OPCRar conditions results in no loss of activity in up to 10% ethanol. This is a significant yet surprising discovery regarding the application of OPCRar to low cost point-of-care devices. Since the conventional wisdom of PCR and isothermal amplification typically advise users to provide the highly purified nucleic acid input that is free of alcohol and salt. As the result, almost all the researchers are employing some kind of vacuum dry, air dry, spin down or heating steps between the alcohol-based washes and eluting the target nucleic acid from nucleic acid-affinity microbeads, glass frit, matrix or filter etc before they run the sample through the PCR amplification process. For instance of an integrated point of care diagnostic device, in addition to amplification and detection of nucleic acids, the devices must also rapidly isolate target nucleic acids. Generally this is performed by binding nucleic acid to a glass fiber matrix and washing in the presence of significant concentrations of salt and ethanol, subsequently eluting in buffer containing minimal salt and no ethanol. Before elution, wash buffer retained on the binding matrix is removed to prevent carry-over to the elution volume; in commercial nucleic acid isolation kits this is typically performed by centrifugation. The specific enzyme mixture of OPCRar eliminates this need for careful removal of ethanol during nucleic acid isolation, making this embodiment of the invention tailored for low cost integrated diagnostics that does not require a vacuum, centrifuge, air dry or heating dry component.
Primers
(76) Oligonucleotide primers as described here can be synthesized and purified by methods known in the art. (See, for example U.S. Pat. No. 6,214,587). In present embodiments, two sequence-specific primers, representing a primer pair are used to exponentially amplify a target nucleic acid sequence. The first primer hybridizes to the upstream 5′ region of the target nucleic acid, and the second primer hybridizes to the downstream, 3′ region of the target sequence. The primers hybridize to the 5′ end of one strand present in the target duplex, and the primers are extended by a polymerase in a 5′ to 3′ direction using the target nucleotide sequence as a template (
(77) Oligonucleotide primer design involves several parameters such as melting temperature and intra- and inter-primer sequence alignment. Melting temperature is governed by factors such as the primer length and GC content. Inter-primer sequence complements can result in hairpin structures, which can impede efficient amplification, whereas intra-primer homology can result in unwanted amplification products dubbed primer-dimers. When designing a primer, it is important to select a sequence within the target which is specific to the nucleic acid molecule to be amplified and will minimally interact with either itself or other primers present in the amplification reaction.
(78) In most nucleic acid amplification strategies, the melting temperature of a primer is preferably about 10 to 30° C. higher than the temperature at which the hybridization and amplification takes place. With the temperature of the annealing/polymerization stage(s) being 55-60° C. in a PCR reaction, primers are typically 18-30 base pairs in length. This specific oligonucleotide length is minimized to allow for easy primer binding without loss of sequence specificity. In the OPCRar system, however, primers are preferably designed to be unusually long at 35-55 base pairs, with a melting temperature preferably between 70-80° C. in order to raise the temperature of the annealing stage. Considering the levels of the duplex destabilizing agent, DMSO, used in a typical OPCRar reaction (˜10-15%), the calculated Tm of OPCRar primers is preferably only <10° C. above the annealing temperature used during thermal cycling. In experiments and with the extreme length of OPCRar primers, efficient amplification occurs despite a minimal difference in primer Tm (compensating for the concentration of DMSO) and the annealing/elongation temperature.
(79) Referring now to
(80) Referring now to
(81) Referring now to
(82) In order to minimize the potential for primer dimer formation, OPCRar primers may be designed to employ several strategies differing from those used to generate conventional PCR primers. First, PCR primers generally possess a GC rich 3′ end called a ‘GC clamp’, which results in greater specific binding to the target sequence. In OPCRar primers, however, it has been observed that a high GC content in the 3′ region of the primer results in greater primer dimer formation, thus, OPCRar primers are made to contain AT rich 3′ regions to energetically reduce the affinity of 3′-3′ primer interactions resulting in these unwanted amplification products (
(83) TABLE-US-00001 EU AT Forward (SEQ ID NO 21) GTTCTTGTAG CGTTGCAGTC TTCTGCGGAA GATAAGGAAT TGCTTT Reverse (SEQ ID NO 22) GGGCACGTTT ATTAGCAACA ATAGAAGGAT CAAGCATCTG CACAGAAAT EU GC Forward (SEQ ID NO 23) CTTGTAGCGT TGCAGTCTTC TGCGGAAGAT AAGGAATTGC TTTCTGCG Reverse (SEQ ID NO 24) CACGTTTATT AGCAACAATA GAAGGATCAA GCATCTGCAC AGAAATCACCG EU-Atmod Forward (SEQ ID NO 25) GGTGTTCTTG TATCGTTGCA GTCTTCTGCG GAAGATAAGG AATTGCTTT Reverse (SEQ ID NO 26) GTAATGGGCA CGTTTATTAG CAACGATAGA AGGATCAAGC AACTGCACAG AAAT EU GCmod Forward (SEQ ID NO 27) CTTGTATCGT TGCAGTCTTC TGCGGAAGAT AAGGAATTGC TTTCTGCG Reverse (SEQ ID NO 28) GGCACGTTTA TTAGCAACGA TAGAAGGATC AAGCATCTGC ACAGAAATCA CCG
(84) OPCRar primers may include any of the deoxyribonucleotide bases adenine “A”, thymine “T”, guanine “G” or cytosine “C” and/or one or more ribonucleotide bases, A, C, uraceil “U”, G. Furthermore, OPCRar primers may contain one or more modified deoxyribonucleotide or ribonucleotide bases where the modification does not prevent primer hybridization to the target nucleic acid, primer elongation by polymerase, or denaturation of duplex nucleic acid. OPCRar primers may be modified with chemical groups such as methylphosphonates or phosphorothioates, with non-nucleotide linkers, with biotin, or with fluorescent labels such as the amine-reactive fluorescein ester of carboxyfluorescein. Such modifications may enhance primer performance or facilitate the detection and characterization of amplification products.
Polymerases
(85) After single stranded template nucleic acid region has hybridized with a primer during OPCRar, a polymerization step occurs. If the target nucleic acid is DNA, a DNA polymerase is selected which acts on the target to extend the hybridized primers along the nucleic acid template in the presence of the four dNTP nucleotide bases to form a double stranded product where the newly synthesized strand is complementary to the nucleotide sequence of the template (
(86) A variety of DNA polymerases may be selected for OPCRar on the basis of thermostability and processivity, especially in the presence of the destabilizing agent, and alcohol (
Single-Stranded Binding Proteins
(87) The OPCRar system preferably minimizes the temperature differential between melting and annealing thermal cycling stages, where this temperature differential is lowest if complete denaturation of duplex nucleic acid is unnecessary. While a strand-displacing DNA polymerase is helpful in this regard, accessory proteins may be used to further lower the thermal requirements for efficient amplification. Single-stranded binding proteins (SSBs) are known to stabilize single stranded nucleic acid to prevent the annealing of double stranded duplex formation, and have been shown to increase the efficiency of nucleic acid amplification reactions. The addition of a thermostable SSB to OPCRar methods according to an embodiment of the present invention is found to result in improved activity (
(88) Referring now to
(89) In addition to thermostable SSBs that aid OPCRar, non-thermostable SSBs such as T4 bacteriophage SSB (New England BioLabs) may be used to reduce primer dimer formation in the initial heating of the OPCRar solution (
(90) The OPCRar method is particularly well suited for use with a device such as that described in the commonly owned provisional patent application filed on the same date hereof, entitled “INTEGRATED DEVICE FOR NUCLEIC ACID DETECTION AND IDENTIFICATION”. The configuration of certain embodiments of that device enables the temperature of a solution to rapidly cycle while the solution remains in the same chamber, preferably without active cooling. For example, the temperature could increase or decrease sufficiently to perform OPCRar in less than or equal to 20 seconds, or more preferably less than or equal to 15 seconds, or more preferably less than or equal to about 8 seconds, or more preferably less than or equal to about 4 seconds. Thus and OPCRar temperature cycle could be performed in as little as, or even faster than, 8 seconds.
Example 1: Method of Amplification of a DNA Target Duplex by OPCRar
(91) To demonstrate that OPCRar is capable of amplifying a specific target sequence present in a double stranded DNA analyte, we used two OPCRar primers, primer HLB (Huang Long Bing) ForSh and primer HLBRevSh, to generate a 140 bp sequence from a PCR-amplified fragment of the C. Liberibacter asiaticus elongation factor gene by the OPCRar system. OPCRar Buffer (10×) was premade and contained 400 mM Tris-HCl (pH 8.4), 10 mM ammonium sulfate, 100 mM potassium chloride, and 0.25% Triton X-100. A 20 μL OPCRar solution was set up by mixing: 8.4 μL water 2.0 μL 10× OPCRar Buffer 3.0 μL DMSO 0.4 μL potassium chloride (2 M) 0.5 μL magnesium chloride (100 mM) 0.5 μL dithiothreitol (100 mM) 0.5 μL dNTPs (10 mM) 2.0 μL Primer set HLBForSh and HLBRevSh (4 μM each) 0.5 μL VentR (exo-) DNA Polymerase (2 U/μL) 0.2 μL Et SSB, Extreme Thermostable Single Stranded Binding Protein (500 μg/mL) 2.0 μL of PCR product dilution (0.6 to 0.0006 ng/μL starting concentration)
(92) The reaction was heated at 85° C. for 2 minutes to denature the template and then cycled 40 times, oscillating between 80° C. for 5 seconds, and 65° C. for 5 seconds. After the reactions were complete, 5 μL of OPCRar product was mixed with 2 μL of 6× Sample Loading Buffer (New England BioLabs) and 1 μL of formamide, run on a 12% acrylamide gel, and visualized with ethidium bromide. A 140 bp product was clearly observed at all dilutions shown, and matches the predicted length of the OPCRar target sequence (
(93) Referring now to
Example 2: Method of Amplification of a Single Stranded DNA Target by OPCRar
(94) To demonstrate that OPCRar is capable of amplifying a specific target sequence from a single stranded DNA template, we used OPCRar primers FP3 and RP4 to generate a 153 bp sequence from a commercially available Universal Influenza A template (Biosearch Technologies, Inc.) by the OPCRar system. 10×OPCRar Buffer contains 400 mM Tris-HCl (pH 8.4), 10 mM ammonium sulfate, 100 mM potassium chloride, and 0.25% Triton X-100. A 20 μL OPCRar solution was set up by mixing: 8.4 μL water 2.0 μL 10× OPCRar Buffer 3.0 μL DMSO 0.4 μL potassium chloride (2 M). 0.5 μL magnesium chloride (100 mM) 0.5 μL dithiothreitol (100 mM) 0.5 μL dNTPs (10 mM) 2.0 μL Primer set FP3 and RP4 (8 μM each) 0.5 μL VentR (exo-) DNA Polymerase (2 U/μL) 0.2 μL Et SSB, Extreme Thermostable Single Stranded Binding Protein (500 μg/mL) 2.0 μL of single stranded DNA template (1E9 to 1E2 copies/μL).
(95) As a comparison of sensitivity, a real time PCR reaction was run using identical template concentrations as that used for the above OPCRars. 10× ThermoPol (New England BioLabs) contains 200 mM Tris-HCl (pH 8.8), 100 mM ammonium sulfate, 100 mM potassium chloride, 20 mM magnesium sulfate, and 1% Triton X-100. A 15 μL RT-PCR solution was set up by combining: 9.7 μL water 1.5 μL 10× ThermoPol Buffer 0.4 μL dNTPs (10 mM) 1.5 μL Primer set UniAfCDC/UniArCDC (4 μM each) including TagMan probe UniApCDC (1 μM) 0.4 μL Taq Polymerase (5 U/μL) 1.5 μL single stranded DNA template (1E9 to 1E2 copies/μL)
(96) A serial dilution of universal Influenza A single stranded DNA template between 1E9 to 1E2 copies/μL was amplified by OPCRar in the presence of 15% DMSO, and real time PCR using a TagMan probe. OPCRar reactions were first heated to 85° C. for 2 minutes, then cycled between 80° C. for 15 sec and 65° C. for 15 sec, repeated 40 times. RT-PCR reactions were heated to 95° C. for 2 minutes, then cycled 45 times between 95° C. for 10 sec and 58° C. for 40 sec. After the reactions were complete, 5 μL of OPCRar product was mixed with 2 μL of 6× Sample Loading Buffer (New England BioLabs) and 1 μL of formamide, run on a 12% acrylamide gel, and visualized with ethidium bromide. A 153 bp product was clearly observed for all samples (
(97) Referring now to
Example 3: Method of Amplification of a Specific Sequence Present on Plasmid DNA by OPCRar
(98) To demonstrate that OPCRar is capable of amplifying a specific target sequence present in a double stranded plasmid DNA, we used two OPCRar primers, primer hyvl_For and primer hyvl_Rev, to generate a 139 bp sequence from a plasmid containing the C. Liberibacter asiaticus hyvl gene by the OPCRar system. OPCRar Buffer (10×) was premade and contained 400 mM Tris-HCl (pH 8.4), 10 mM ammonium sulfate, 100 mM potassium chloride, and 0.25% Triton X-100. A 20 μL OPCRar solution was set up by mixing: 9.4 μL water 2.0 μL 10× OPCRar Buffer 2.0 μL DMSO 0.4 μL potassium chloride (2 M) 0.5 μL magnesium chloride (100 mM) 0.5 μL dithiothreitol (100 mM) 0.5 μL dNTPs (10 mM) 2.0 μL Primer set hyvl_For and hyvl_Rev (8 μM each) 0.5 μL VentR (exo-) DNA Polymerase (2 U/μL) 0.2 μL Et SSB, Extreme Thermostable Single Stranded Binding Protein (500 μg/mL) 2.0 μL of DNA extracted from healthy and C. Liberibacter infected tissue (17.2 ng/μL)
(99) A titration with DMSO was performed from 13-8% v/v. The reaction was heated at 85° C. for 2 minutes to denature the template and then cycled 40 times, oscillating between 80° C. for 10 seconds, and 65° C. for 10 seconds. After the reactions were complete, 5 μL of OPCRar product was mixed with 2 μL of 6× Sample Loading Buffer (New England BioLabs) and 1 μL of formamide, run on a 12% acrylamide gel, and visualized with ethidium bromide. A 139 bp product was clearly observed for all samples (
(100) Referring now to
Example 4: Method of Amplification of a RNA Target Sequence of a Human Pathogenic Virus Present in Nasal Aspirate by OPCRar
(101) To demonstrate that OPCRar is capable of amplifying a specific target sequence present in a single stranded RNA template, we used the OPCRar primer pair, FP3 and RP4, to generate a 153 bp sequence from ribonucleic acid isolated from clinical nasal aspirates either infected or uninfected with Influenza A virus. OPCRar Buffer (10×) was premade and contained 400 mM Tris-HCl (pH 8.4), 10 mM ammonium sulfate, 100 mM potassium chloride, and 0.25% Triton X-100. A 20 μL OPCRar solution was set up by combining: 9.3 μL water 2.0 μL 10× OPCRar Buffer 3.0 μL DMSO 0.4 μL potassium chloride (2 M) 0.5 μL magnesium chloride (100 mM) 0.5 μL dithiothreitol (100 mM) 0.5 μL dNTPs (10 mM) 2.0 μL Primer set FP3 and RP4 (8 μM each) 0.5 μL VentR (exo-) DNA Polymerase (2 U/μL) 0.2 μL Et SSB, Extreme Thermostable Single Stranded Binding Protein (500 μg/mL) 0.1 μL Superscript III Reverse Transcriptase (200 U/μL) 2.0 μL of Nucleic acid isolated from clinical Nasal Aspirate (0.3 ng/μL)
(102) The reaction was incubated at 55° C. for 5 minutes to generate cDNA, heated to 85° C. for 2 minutes to denature the template and then cycled 40 times, oscillating between 80° C. for 10 seconds, and 65° C. for 10 seconds. After the reactions were complete, 5 μL of OPCRar product was mixed with 2 μL of 6× Sample Loading Buffer (New England BioLabs) and 1 μL of formamide, run on a 12% acrylamide gel, and visualized with ethidium bromide. A 153 bp product was clearly observed in the positive, but not negative clinical sample (
(103) Referring now to
Example 5: Method of Amplification of a Target Sequence from a Pathogenic Plant Bacteria by OPCRar
(104) To demonstrate that OPCRar is capable of amplifying a specific target sequence present in a pathogenic bacterial genome, we used the OPCRar primer pair, EU523377-F-57 and EU523377-R-56, to generate a 213 by fragment of the C. Liberibacter asiaticus elongation factor gene from total nucleic acid isolated from infected plant tissue. OPCRar Buffer (10×) was premade and contained 400 mM Tris-HCl (pH 8.4), 10 mM ammonium sulfate, 100 mM potassium chloride, and 0.25% Triton X-100. A 20 μL OPCRar solution was set up by combining: 8.4 μL water 2.0 μL 10× OPCRar Buffer 3.0 μL DMSO 0.4 μL potassium chloride (2 M) 0.5 μL magnesium chloride (100 mM) 0.5 μL dithiothreitol (100 mM) 0.5 μL dNTPs (10 mM) 2.0 μL Primer set EU523377-F-57 and EU523377-R-56 (4 μM each), primer EU523377-F-57 was either biotinylated (5′) or non-biotinylated 0.5 μL VentR (exo-) DNA Polymerase (2 U/μL) 0.2 μL Et SSB, Extreme Thermostable Single Stranded Binding Protein (500 μg/mL) 2.0 μL of Total nucleic acid isolated from C. Liberibacter aslaticus infected plant tissue (1.1 ng/μL)
(105) To demonstrate that primer modifications are compatible with OPCRar, the forward primer EU523377-F-57 was biotinylated at the 5′ end in some reactions. OPCRar solutions were heated at 85° C. for 2 minutes to denature the template and then cycled 40 times, oscillating between 80° C. for 15 seconds, and 65° C. for 15 seconds. After the reactions were complete, 5 μL of OPCRar product was mixed with 2 μL of 6× Sample Loading Buffer (New England BioLabs) and 1 μL of formamide, run on a 12% acrylamide gel, and visualized with ethidium bromide. A 213 bp product was clearly observed for all samples, and matches the predicted length of the OPCRar target sequence (
(106) Referring now to
Example 6: Method of Amplification of a Specific Sequence on Organelle DNA
(107) To demonstrate that OPCRar is capable of amplifying a specific target sequence present in organelle DNA, in this case chloroplast DNA, we used the OPCRar primer pair, rbcL_For and rbcL_Rev, to generate a 137 bp fragment of the rbcL gene of plant from total nucleic acid isolated from plant tissue either infected or uninfected with C. Liberibacter asiaticus. OPCRar Buffer (10×) was premade and contained 400 mM Tris-HCl (pH 8.4), 10 mM ammonium sulfate, 100 mM potassium chloride, and 0.25% Triton X-100. A 20 μL OPCRar solution was set up by combining: 8.4 μL water 2.0 μL 10× OPCRar Buffer 3.0 μL DMSO 0.4 μL potassium chloride (2 M) 0.5 μL magnesium chloride (100 mM) 0.5 μL dithiothreitol (100 mM) 0.5 μL dNTPs (10 mM) 2.0 μL Primer set rbcL_For and rbcL_Rev (2 or 4 μM each) 0.5 μL VentR (exo-) DNA Polymerase (2 U/μL) 0.2 μL Et SSB; Extreme Thermostable Single Stranded Binding Protein (500 μg/mL) 2.0 μL of Total nucleic acid isolated from leaf tissue (3.3 ng/μL)
(108) Two different concentrations of the primer pair rbcL_For and rbcL_Rev were used to determine a threshold for the primer concentration necessary to efficiently amplify the rbcL gene fragment. The reaction was heated at 85° C. for 2 minutes to denature the template and then cycled 40 times, oscillating between 76° C. for 10 seconds, and 60° C. for 10 seconds. After the reactions were complete, 5 μL of OPCRar product was mixed with 2 μL of 6× Sample Loading Buffer (New England BioLabs) and 1 μL of formamide, run on a 12% acrylamide gel, and visualized with ethidium bromide. A 137 bp product was clearly observed for both infected and uninfected samples, and matches the predicted length of the OPCRar target sequence (
(109) Referring now to
(110) Example 7: Method of Multiplex Amplification of a Target Sequence and Positive Control by OPCRar
(111) To demonstrate that OPCRar is capable of amplifying multiple specific target sequences, we amplified the nucleic acid extracted from C. Liberibacter asiaticus infected plant tissue with the OPCRar primer pairs, hyvl_For/hyvl_Rev, and rbcL_For/rbcL_Rev. These primer sets generate products of 139 and 137 bp, respectively. OPCRar Buffer (10×) was premade and contained 400 mM Tris-HCl (pH 8.4), 10 mM ammonium sulfate, 100 mM potassium chloride, and 0.25% Triton X-100. A 20 μL OPCRar solution was set up by combining: 6.4 μL water 2.0 μL 10× OPCRar Buffer 3.0 μL DMSO 0.4 μL potassium chloride (2 M) 0.5 μL magnesium chloride. (100 mM) 0.5 μL dithiothreitol (100 mM) 0.5 μL dNTPs (10 mM) 2.0 μL Primer set rbcL_For and rbcL_Rev (2 or 3 μM each) 2.0μ Primer set hyvl_For and hyvl_Rev (8 μM each) 0.5 μL VentR (exo-) DNA Polymerase (2 U/μL) 0.2 μL Et SSB, Extreme Thermostable Single Stranded Binding Protein (500 μg/mL) 2.0 μL of Total nucleic acid isolated from leaf tissue (3.3 ng/μL)
(112) Two different concentrations of the primer pair rbcL_For and rbcL_Rev were used to determine a threshold for the primer concentration necessary to efficiently amplify the rbcL gene fragment in the presence of 800 nM primers specific for the hyvl gene fragment. The reaction was heated at 85° C. for 2 minutes to denature the template and then cycled 40 times, oscillating between 76° C. for 10 seconds, and 60° C. for 10 seconds. After the reactions were complete, 5 μL of OPCRar product was mixed with 2 μL of 6× Sample Loading Buffer (New England BioLabs) and 1 μL of formamide, run on a 12% acrylamide gel, and visualized with ethidium bromide. Both 139 bp and 137 bp products are clearly observed, matching the predicted length of the OPCRar target sequences. For clarity, OPCRar products generated using both primer pairs alone (Examples 3 and 6) were run alongside the multiplex reactions (
(113) Referring now to
(114) Referring now to
(115) Referring now to
(116)
(117) Referring now to
(118) All primer melting temperatures (Tm) calculated using IDT OligoAnalyzer 3.1 (Integrated DNA Technologies, Inc., Coralville, Iowa) using the Primer 3 Tm calculating software where salt, dNTP, Mg, primer concentration parameters are considered using the following parameters:
(119) Oligonucleotide Concentration: 0.25 μM; Na.sup.30Concentration: 50 mM; Mg.sup.++ Concentration=2.5 mM; dNTPs Concentration=0.25 μM. Symbol “a” means adenine, “g” means guanine, “c” means cytosine, “t” means thymine, “u” means uracil, “r” means purine, ∂y” means pyrimidine, “m” means amino, “k” means keto, “n” means any of a or g or c or t/u, unknown, or other.
(120) (SEQ ID NO 1)
(121) ACCESSION NUMBER: CY087034
(122) TYPE: Viral RNA
(123) LENGTH: 1010
(124) ORGANISM: Influenza A Virus (H1N1)
(125) OTHER INFORMATION: matrix protein 2 (M2) and matrix protein 1 (M1) genes
(126) (SEQ ID NO 2)
(127) TYPE: Forward Primer
(128) NAME: FP3
(129) LENGTH: 46
(130) Tm: mean 75° C.
(131) (SEQ ID NO 3)
(132) TYPE: Reverse Primer
(133) NAME: RP3
(134) LENGTH: 40
(135) Tm: mean 77.8° C.
(136) (SEQ ID NO 4)
(137) TYPE: Reverse Primer
(138) NAME: RP4
(139) LENGTH: 46
(140) Tm: mean 74.7° C.
(141) (SEQ ID NO 5)
(142) TYPE: Forward Primer
(143) NAME: UniAfCDC
(144) LENGTH: 22
(145) Tm: mean 65.0° C.
(146) (SEQ ID NO 6)
(147) TYPE: Reverse Primer
(148) NAME: UniArCDC
(149) LENGTH: 24
(150) Tm: mean 66.6° C.
(151) TABLE-US-00002 (SEQ ID NO 7) FAM-tgcagtcctc gctcactggg cacg-BHQ
TYPE: TagMan Probe
NAME: UniApCDC
LENGTH: 24
Tm: 73.4° C.
(152) (SEQ ID NO 8)
(153) ACCESSION NUMBER: AB505957
(154) TYPE: Chloroplast DNA
(155) LENGTH: 1326
(156) ORGANISM: Citrus sinensis
(157) OTHER INFORMATION: rbcL, ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit
(158) (SEQ ID NO 9)
(159) TYPE: Forward Primer
(160) NAME: rbcL_For
(161) LENGTH: 38
(162) Tm: 73.9° C.
(163) (SEQ ID NO 10)
(164) TYPE: Reverse Primer
(165) NAME: rbcL_Rev
(166) LENGTH: 43
(167) Tm: 71.2° C.
(168) (SEQ ID NO 11)
(169) ACCESSION NUMBER: From EU523377
(170) TYPE: Bacterial DNA
(171) LENGTH: 890
(172) ORGANISM: Candidatus Liberibacter asiaticus
(173) OTHER INFORMATION: elongation factor Ts
(174) (SEQ ID NO 12)
(175) TYPE: Forward Primer
(176) NAME: NBEU523377-F-57
(177) LENGTH: 57
(178) Tm: 75.8° C.
(179) TABLE-US-00003 (SEQ ID NO 13) [Biotin-5]tcttcgtatc ttcatgcttc tccttctgag ggtttaggat cgattggtgt tcttgta
TYPE: Biotinylated Forward Primer
NAME: EU523377-F-57
LENGTH: 57
Tm: 75.8° C.
(180) (SEQ ID NO 14)
(181) TYPE: Forward Primer
(182) NAME: HLBForSh
(183) LENGTH: 47
(184) Tm: 75.6° C.
(185) (SEQ ID NO 15)
(186) TYPE: Reverse Primer
(187) NAME: EU523377-R-56
(188) LENGTH: 56
(189) Tm: 75.8° C.
(190) (SEQ ID NO 16)
(191) TYPE: Reverse Primer
(192) NAME: HLBRevSh
(193) LENGTH: 49
(194) Tm: 75.5° C.
(195) (SEQ ID NO 17)
(196) TARGET: Candidatus Liberibacter asiaticus 16S ribosomal RNA
(197) TYPE: Forward Primer (underlined), contains 5′ detection sequence
(198) NAME: HLBas-P2
(199) LENGTH: 39
(200) Tm: 62.7° C.
(201) (SEQ ID NO 18)
(202) TARGET: Candidatus Liberibacter asiaticus 16S ribosomal RNA
(203) TYPE: Reverse Primer (underlined), contains 5′ T7 promoter
(204) NAME: HLBr-P1
(205) LENGTH: 56
(206) Tm: 64.5° C.
(207) (SEQ ID NO 19)
(208) TYPE: Forward Primer
(209) NAME: hyvl_For
(210) LENGTH: 45
(211) Tm: 72.2° C.
(212) (SEQ ID NO 20)
(213) TYPE: Reverse Primer
(214) NAME: hyvl_Rev
(215) LENGTH: 51
(216) Tm: 70.9° C.
(217) Although the invention has been described in detail with particular reference to the described embodiments, other embodiments can achieve the same results. Variations and modifications of the present invention will be obvious to those skilled in the art and it is intended to cover all such modifications and equivalents. The entire disclosures of all patents and publications cited above are hereby incorporated by reference.